Line 4: |
Line 4: |
| ==Primary Author(s)*== | | ==Primary Author(s)*== |
| Parastou Tizro, MD, Celeste C. Eno, PhD, Sumire Kitahara, MD | | Parastou Tizro, MD, Celeste C. Eno, PhD, Sumire Kitahara, MD |
| + | |
| + | Cedars-Sinai, Los Angeles, CA |
| ==WHO Classification of Disease== | | ==WHO Classification of Disease== |
| {| class="wikitable" | | {| class="wikitable" |
Line 207: |
Line 209: |
| **5 x 10<sup>9</sup>/L cells of T PLL phenotype in peripheral blood or bone marrow | | **5 x 10<sup>9</sup>/L cells of T PLL phenotype in peripheral blood or bone marrow |
| **T cell clonality by molecular or flow cytometry methods | | **T cell clonality by molecular or flow cytometry methods |
− | **Abnormalities of 14q32 or Xq28 or expression of TCL1A/B or MTC** | + | **Abnormalities of 14q32 or Xq28 or expression of TCL1A/B or MTC** |
| *'''Minor criteria:''' | | *'''Minor criteria:''' |
| **Abnormalities involving chromosome 11 | | **Abnormalities involving chromosome 11 |
Line 371: |
Line 373: |
| The genetic diagnostic process involves detecting clonal rearrangements of the TR gene and rearrangements of the ''TCL1'' gene at the ''TRB'' or ''TRG'' loci. | | The genetic diagnostic process involves detecting clonal rearrangements of the TR gene and rearrangements of the ''TCL1'' gene at the ''TRB'' or ''TRG'' loci. |
| | | |
− | * Cytogenetics (FISH, CpG-stimulated Karyotype, SNP microarray) | + | *Cytogenetics (FISH, CpG-stimulated Karyotype, SNP microarray) |
− | * PCR for TRB/TRG | + | *PCR for TRB/TRG |
− | * Next-Generation Sequencing (NGS) | + | *Next-Generation Sequencing (NGS) |
| | | |
| ==Familial Forms== | | ==Familial Forms== |